<DOC>
	<DOCNO>NCT02152345</DOCNO>
	<brief_summary>The main purpose study ﬁnd whether treatment prevent kidney rejection belatacept presence Thymoglobulin induction withdrawal steroid result less delay graft function `` sleepy kidney '' transplant see patient get tacrolimus main drug prevent rejection instead belatacept . The investigator also look whether patient get belatacept , less problem get tacrolimus .</brief_summary>
	<brief_title>Belatacept Compared Tacrolimus Deceased Donor Renal Transplant Recipients</brief_title>
	<detailed_description>New York Presbyterian Hospital-Columbia University Medical Center ( NYPH-CUMC ) perform nearly 250 renal transplant annually ; approximately half recipient variety decease donor kidney , usually cold ischemia time ( CIT ) &gt; 24 hour lead approximate incidence delay graft function ( DGF ) 50 % . The main focus study determine whether initial immunosuppression belatacept Thymoglobulin induction result low incidence and/or rapid disappearance DGF observe patient receive tacrolimus base immunosuppression . NGAL determination bne make first month transplantation correlate clinical DGF .</detailed_description>
	<mesh_term>Delayed Graft Function</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients must know EpsteinBarr virus ( EBV ) serostatus , status must positive Adult patient ≥18 year age , receive decease donor kidney transplant Columbia University Medical Center ( CUMC ) Patients PRA ≤ 50 Primary retransplant candidate ( 5th renal transplant ) Deceased donor renal transplant recipient Candidates eligible rATG induction Patients fully consent prior transplantation Women reproductive age willing delay pregnancy duration study use appropriate recommend contraception Seronegative unknown EBV serologic status ( due risk posttransplant lymphoproliferative disorder , PTLD ) , predominantly involve central nervous system . Patients tuberculosis treat latent infection . Scheduled undergo multiorgan transplantation Recipients previous nonrenal organ transplant Patient receive 5th renal transplant time screen . Patients PRA &gt; 50 Recipient preemptive status . Recipient positive flow crossmatch . History known HIV Known hypersensitivity contraindication Belatacept , Tacrolimus , Mycophenolate mofetil ( cellcept ) , mycophenolic acid Use investigational drug past 30 day day surgery Enrolled clinical trial current Lactating pregnant woman Donor specific antibody ( DSA ) identify time transplantation ABO incompatible renal transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>kidney</keyword>
	<keyword>renal</keyword>
	<keyword>transplant</keyword>
	<keyword>belatacept</keyword>
	<keyword>delay graft function</keyword>
	<keyword>thymoglobulin</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>kidney function</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>NGAL</keyword>
</DOC>